Altimmune, Inc. (ALT) vs Arvinas, Inc. (ARVN)
- Altimmune, Inc. ALT 2.48 −3.13%
- Arvinas, Inc. ARVN 7.14 −4.16%
Altimmune, Inc. and Arvinas, Inc. are both Biotechnology companies. Altimmune, Inc. and Arvinas, Inc. are of similar size ($507.7M and $499.6M). Altimmune, Inc. has negative trailing earnings, so its P/E is not meaningful; Arvinas, Inc. trades at 57.3×. Altimmune, Inc. grew revenue faster over the last twelve months: 130.0% against −15.1%. Arvinas, Inc. has the higher net margin (2.94% vs 0.00%) and the higher return on invested capital (0.00% vs −34.3%). Across the 18 metrics below, Arvinas, Inc. leads on 11 and Altimmune, Inc. on 7.
Valuation
Profitability
| Metric | ALT | ARVN | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 97.16% | 65.16% |
| Operating margin | 0.00% | (5.72%) | 0.00% |
| Net margin | 0.00% | 2.94% | 0.00% |
| Free cash flow margin | 0.00% | (65.93%) | 0.00% |
| Return on equity | (28.87%) | 1.59% | (56.66%) |
| Return on assets | (25.58%) | 1.17% | (49.22%) |
| Return on invested capital | (34.30%) | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack